OptiNose Future Growth
Future criteria checks 5/6
OptiNose is forecast to grow earnings and revenue by 70% and 27.9% per annum respectively while EPS is expected to grow by 71.6% per annum.
Key information
70.0%
Earnings growth rate
71.6%
EPS growth rate
Pharmaceuticals earnings growth | 23.9% |
Revenue growth rate | 27.9% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 13 Nov 2024 |
Recent future growth updates
Recent updates
OptiNose, Inc. (NASDAQ:OPTN) Might Not Be As Mispriced As It Looks After Plunging 31%
Nov 26Earnings Release: Here's Why Analysts Cut Their OptiNose, Inc. (NASDAQ:OPTN) Price Target To US$3.50
Nov 15Slammed 34% OptiNose, Inc. (NASDAQ:OPTN) Screens Well Here But There Might Be A Catch
Sep 27Market Cool On OptiNose, Inc.'s (NASDAQ:OPTN) Revenues Pushing Shares 30% Lower
Aug 11Not Many Are Piling Into OptiNose, Inc. (NASDAQ:OPTN) Stock Yet As It Plummets 42%
Apr 27There's Reason For Concern Over OptiNose, Inc.'s (NASDAQ:OPTN) Massive 32% Price Jump
Mar 01Revenues Working Against OptiNose, Inc.'s (NASDAQ:OPTN) Share Price
Dec 28OptiNose, Inc. (NASDAQ:OPTN) Might Not Be As Mispriced As It Looks After Plunging 29%
May 23The Consensus EPS Estimates For OptiNose, Inc. (NASDAQ:OPTN) Just Fell Dramatically
Mar 09OptiNose GAAP EPS of -$0.23 beats by $0.01, revenue of $20.6M misses by $0.9M
Aug 11OptiNose: Potential Winner In Chronic Sinusitis Treatment
Jun 16OptiNose: Underappreciated Potential
Mar 10Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 154 | 6 | 42 | 25 | 3 |
12/31/2025 | 121 | -13 | 22 | -1 | 4 |
12/31/2024 | 79 | -28 | -6 | -20 | 4 |
9/30/2024 | 76 | -31 | -40 | -40 | N/A |
6/30/2024 | 75 | -41 | -36 | -35 | N/A |
3/31/2024 | 74 | -31 | -32 | -32 | N/A |
12/31/2023 | 71 | -35 | -21 | -21 | N/A |
9/30/2023 | 72 | -41 | -45 | -45 | N/A |
6/30/2023 | 72 | -46 | -58 | -58 | N/A |
3/31/2023 | 73 | -68 | -59 | -59 | N/A |
12/31/2022 | 76 | -75 | -68 | -68 | N/A |
9/30/2022 | 78 | -75 | -67 | -67 | N/A |
6/30/2022 | 80 | -77 | -59 | -59 | N/A |
3/31/2022 | 77 | -82 | -68 | -68 | N/A |
12/31/2021 | 75 | -82 | -77 | -77 | N/A |
9/30/2021 | 68 | -91 | -80 | -79 | N/A |
6/30/2021 | 62 | -95 | -86 | -85 | N/A |
3/31/2021 | 54 | -97 | -87 | -86 | N/A |
12/31/2020 | 49 | -100 | -87 | -86 | N/A |
9/30/2020 | 44 | -101 | -86 | -85 | N/A |
6/30/2020 | 41 | -109 | -85 | -85 | N/A |
3/31/2020 | 37 | -110 | -90 | -89 | N/A |
12/31/2019 | 35 | -110 | -91 | -91 | N/A |
9/30/2019 | 27 | -111 | -94 | -93 | N/A |
6/30/2019 | 16 | -108 | -103 | -102 | N/A |
3/31/2019 | 11 | -105 | -100 | -99 | N/A |
12/31/2018 | 7 | -107 | -94 | -92 | N/A |
9/30/2018 | 4 | -101 | -88 | -85 | N/A |
6/30/2018 | 2 | -93 | N/A | -70 | N/A |
3/31/2018 | 1 | -81 | N/A | -51 | N/A |
12/31/2017 | N/A | -62 | N/A | -36 | N/A |
9/30/2017 | N/A | -43 | N/A | -28 | N/A |
6/30/2017 | N/A | -35 | N/A | -24 | N/A |
3/31/2017 | N/A | -46 | N/A | -24 | N/A |
12/31/2016 | 48 | 2 | N/A | 22 | N/A |
12/31/2015 | 0 | -40 | N/A | -29 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OPTN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: OPTN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: OPTN is expected to become profitable in the next 3 years.
Revenue vs Market: OPTN's revenue (27.9% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: OPTN's revenue (27.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OPTN's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 05:48 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
OptiNose, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Gary Nachman | BMO Capital Markets Equity Research |
John Tanner | Cantor Fitzgerald & Co. |
Matthew Caufield | H.C. Wainwright & Co. |